Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1488587
                    [Title] => Low HDL, high LDL linked to cerebral amyloidosis
                    [Summary] => 
A low level of HDL cholesterol and a high level of LDL cholesterol was associated with elevated cerebral amyloid-beta in a small sample of elderly individuals with high vascular risk, representing one of the best efforts yet to determine the link between cholesterol and susceptibility to brain amyloidosis seen in Alzheimer’s disease.

                    [DatePublished] => 2015-08-15 10:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 209261
                    [Title] => NSAIDs for one year failed to show  Alzheimer’s disease
                    [Summary] => Neither the selective cyclooxygenase-2inhibitor rofecoxib nor the nonselective NSAID naproxen slowed the rate of cognitive or functional decline in a one-year, placebo-controlled study of patients with Alzheimer’s disease, it was reported at the Eighth International Conference on Alzheimer’s disease and Related Disorders. 


                    [DatePublished] => 2003-06-08 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

CLINICAL DEMENTIA RATING

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1488587
                    [Title] => Low HDL, high LDL linked to cerebral amyloidosis
                    [Summary] => 
A low level of HDL cholesterol and a high level of LDL cholesterol was associated with elevated cerebral amyloid-beta in a small sample of elderly individuals with high vascular risk, representing one of the best efforts yet to determine the link between cholesterol and susceptibility to brain amyloidosis seen in Alzheimer’s disease.

                    [DatePublished] => 2015-08-15 10:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 209261
                    [Title] => NSAIDs for one year failed to show  Alzheimer’s disease
                    [Summary] => Neither the selective cyclooxygenase-2inhibitor rofecoxib nor the nonselective NSAID naproxen slowed the rate of cognitive or functional decline in a one-year, placebo-controlled study of patients with Alzheimer’s disease, it was reported at the Eighth International Conference on Alzheimer’s disease and Related Disorders. 


                    [DatePublished] => 2003-06-08 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Low HDL, high LDL linked to cerebral amyloidosis

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | August 15, 2015 - 10:00am

A low level of HDL cholesterol and a high level of LDL cholesterol was associated with elevated cerebral amyloid-beta in a small sample of elderly individuals with high vascular risk, representing one of the best...

Opinion

NSAIDs for one year failed to show Alzheimer’s disease

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | June 8, 2003 - 12:00am

Neither the selective cyclooxygenase-2inhibitor rofecoxib nor the nonselective NSAID naproxen slowed the rate of cognitive or functional decline in a one-year, placebo-controlled study of patients with Alzheimer’s...

Opinion